Whereas others have simply reformulated,
we focus on chemistry — and innovation

TAAP™ : Trypsin-Activated Abuse Protection

Our proprietary Trypsin-Activated Abuse Protection (TAAP™) technology prevents abuse through a 2-step internal Trypsin-Activation process. Our prodrugs are chemically stable molecules that are activated only when administered orally. Due to the activating enzymes not being present in the blood or saliva, there is no opportunity for activation if injected, chewed or snorted

Most abuse-deterrent opioid products that are currently marketed or in late-stage clinical development fall short of being fully resistant to abuse. Many of them use “extended-release” (ER) formulations. However, ER formulations are still prone to abuse by crushing, chewing, or extracting and injecting for an immediate release of active opioid to achieve rapid, spiking blood levels and a euphoric rush.

TAAP™ limits all forms of drug abuse including chewing, inhaling, manipulation and injectionand is adaptable to most prescription drugs having the potential for abuse.

MPAR™ : Multi-Pill Abuse Resistant

Ensysce’s Multi-Pill Abuse Resistant (MPAR™) is an overdose protection technology that is unique to the industry. It provides a Trypsin Inhibitor (TI) that limits activation with increasing ingestion of product.

A small amount of activation inhibitor is added to each TAAP™ product and does not affect the opioid release if taken as prescribed

On the other hand, if a prescription is not taken according to directions, or by accidental overdose, MPAR™ provides protection by way of a Trypsin Inhibitor which blocks the activation and release of the opioid, allowing the pills to pass through the body inactivated.

The National Institute on Drug Abuse awarded Ensysce approximately $12 Million in September 2018 to develop MPAR™.


Single Walled Carbon Nanotubes

Ensysce Biosciences is also focused on the use of carbon nanotubes for the delivery of novel therapeutics. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner, Dr Rick Smalley.

Single walled carbon nanotubes can be used for delivery of nucleic acids for gene therapy and has the ability to overcome the problems by other viral and non-viral platforms.

Ensysce is conducting research on the use of carbon nanotubes for the delivery of oligonucleotides and large biomolecules to progress the technology through preclinical development, by collaborating with research programs at major medical centers, universities and pharm companies.  

Ensysce is looking to accelerate these research programs through outside collaborations, as an avenue to move this novel delivery platform rapidly into the clinic.


For more information on any of our technologies, feel free to contact us.